CBAY logo

Cymabay Therapeutics

CBAY

CBAY: CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

more

Show CBAY Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CBAY by members of U.S. Congress

Politician Type Traded
Roger W. Marshall House / R Sale $1,001 - $15,000 Jul. 19, 2017
Roger W. Marshall House / R Purchase $1,001 - $15,000 Jul. 19, 2017
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CBAY's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Treatment of intrahepatic cholestatic diseases Mar. 07, 2023
  • Patent Title: Treatment of intrahepatic cholestatic diseases Aug. 09, 2022
  • Patent Title: Treatment of intrahepatic cholestatic diseases Jan. 18, 2022
  • Patent Title: Treatment of nafld and nash Nov. 23, 2021
  • Patent Title: Methods of reducing small, dense ldl particles May. 18, 2021
  • Patent Title: Treatment of intrahepatic cholestatic diseases May. 11, 2021
  • Patent Title: Treatment of intrahepatic cholestatic diseases Nov. 10, 2020
  • Patent Title: Treatment of intrahepatic cholestatic diseases Oct. 27, 2020
  • Patent Title: Treatment of intrahepatic cholestatic diseases Oct. 27, 2020
  • Patent Title: Treatment of nafld and nash Jul. 28, 2020
  • Patent Title: Treatment of intrahepatic cholestatic diseases Dec. 24, 2019
  • Patent Title: Treatment of intrahepatic cholestatic diseases Nov. 19, 2019
  • Patent Title: Treatment of nafld and nash Jul. 09, 2019
  • Patent Title: Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions May. 21, 2019
  • Patent Title: Treatment of intrahepatic cholestatic diseases Apr. 30, 2019
  • Patent Title: Treatment of intrahepatic cholestatic diseases Mar. 05, 2019
  • Patent Title: Treatment for nafld and nash Jan. 29, 2019
  • Patent Title: Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent Nov. 27, 2018
  • Patent Title: Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine Oct. 16, 2018
  • Patent Title: Treatment of nafld and nash May. 08, 2018
  • Patent Title: Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders Mar. 27, 2018
  • Patent Title: Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto Dec. 19, 2017
  • Patent Title: Treatment of intrahepatic cholestatic diseases Nov. 07, 2017
  • Patent Title: Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent Oct. 31, 2017
  • Patent Title: Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders Aug. 22, 2017
  • Patent Title: Treatment of nafld and nash Apr. 11, 2017
  • Patent Title: Bicyclic agonists of gpr131 and uses thereof Mar. 14, 2017
  • Patent Title: Treatment of intrahepatic cholestatic diseases Nov. 08, 2016
  • Patent Title: Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent Sep. 13, 2016
  • Patent Title: Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent Sep. 06, 2016
  • Patent Title: Treatment of nafld and nash Jul. 05, 2016
  • Patent Title: Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine Jan. 26, 2016
  • Patent Title: Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto Jan. 12, 2016
  • Patent Title: Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts Oct. 06, 2015
  • Patent Title: Methods for treating gout flares Jun. 23, 2015
  • Patent Title: Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent May. 05, 2015
  • Patent Title: Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto Mar. 31, 2015
  • Patent Title: Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders Mar. 10, 2015
  • Patent Title: Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders Dec. 30, 2014
  • Patent Title: Dcc mediated coupling for halofenate manufacture Dec. 16, 2014
  • Patent Title: N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders Sep. 30, 2014
  • Patent Title: Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts Aug. 26, 2014
  • Patent Title: Agonists of gpr131 and uses thereof Apr. 22, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CBAY in WallStreetBets Daily Discussion

CBAY News

Recent insights relating to CBAY

CNBC Recommendations

Recent picks made for CBAY stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CBAY

Corporate Flights

Flights by private jets registered to CBAY